Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Sells 7,912 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 7,912 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $6.38, for a total value of $50,478.56. Following the sale, the general counsel now directly owns 120,561 shares in the company, valued at $769,179.18. This represents a 6.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Benjamin Jackson also recently made the following trade(s):

• On Friday, January 10th, Benjamin Jackson sold 13,272 shares of Sera Prognostics stock. The shares were sold at an average price of $7.42, for a total value of $98,478.24.
• On Monday, November 11th, Benjamin Jackson sold 4,727 shares of Sera Prognostics stock. The stock was sold at an average price of $7.32, for a total transaction of $34,601.64.

Sera Prognostics Price Performance

Shares of SERA traded up $0.04 during midday trading on Tuesday, reaching $6.37. The stock had a trading volume of 134,610 shares, compared to its average volume of 143,614. The company has a market cap of $215.13 million, a price-to-earnings ratio of -6.43 and a beta of 0.86. The company’s fifty day simple moving average is $7.44 and its two-hundred day simple moving average is $7.31. Sera Prognostics, Inc. has a 1-year low of $4.98 and a 1-year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.09 million. During the same quarter in the previous year, the company posted ($0.23) EPS. On average, sell-side analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

Institutional investors have recently added to or reduced their stakes in the business. Barclays PLC grew its stake in Sera Prognostics by 321.6% during the 3rd quarter. Barclays PLC now owns 39,450 shares of the company’s stock worth $308,000 after buying an additional 30,093 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Sera Prognostics by 100.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after acquiring an additional 75,441 shares during the period. Geode Capital Management LLC lifted its position in Sera Prognostics by 8.9% in the third quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock valued at $4,578,000 after purchasing an additional 47,969 shares during the period. Quest Partners LLC boosted its holdings in Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after purchasing an additional 5,415 shares in the last quarter. Finally, State Street Corp increased its position in Sera Prognostics by 8.8% during the 3rd quarter. State Street Corp now owns 425,093 shares of the company’s stock worth $3,316,000 after purchasing an additional 34,479 shares during the period. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.